Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.77 |
| ▸ | PI4KA | P42356 | 11/20 | 0.77 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.75 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.75 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.75 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.75 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.59 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29646253 | 0.92 | PIK3CA (0.82) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL5532470 | 0.92 | PIK3CA (0.82) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL8773471 | 0.87 | PIK3CA (1.00) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL31114545 | 0.86 | PIK3CA (1.00) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL9722748 | 0.86 | PIK3CA (0.73) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL25303570 | 0.86 | MAPT (0.74) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL3306309 | 0.86 | PIK3CA (0.74) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL31114564 | 0.86 | MAPT (0.74) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL25218319 | 0.86 | PIK3CA (1.00) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL31114470 | 0.86 | PIK3CA (0.73) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-3008061-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| CN-105246891-A | Novel compounds for the treatment of cancer | Bayer Pharma AG | 2016-01-13 | — | — | CN | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BUB1B, PLK1, BRCA1 | PIK3CA 23/4885PI4KA 239/4885PI4KB 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.